Umeclidinium bromide (CAS: 869113-09-7) is a medication used for the treatment of chronic obstructive pulmonary disease (COPD). It was first approved by the US Food and Drug Administration (FDA) in 2014 and has since become widely used as a long-acting bronchodilator for patients with COPD. This article will provide an overview of Umeclidinium bromide, including its chemical properties, health benefits, potential effects, product mechanism, safety, side effects, dosing information, and a conclusion on its use.
Chemical Properties The chemical name for Umeclidinium bromide is [(2R)-2-[(3R)-1-(2-{2-[(2,2-difluoro-2-phenylethyl)amino]-1-hydroxyethyl}-1-azetidinyl)-3-(2-{[(2S)-1-hydroxy-1-oxo-4-propan-2-yl-2-butanyl]oxy}ethoxy)-2,3-dihydro-1H-inden-5-yl]oxy]-2-methylpropanoic acid, bromide. Its molecular formula is C29H34BrN3O6, and it has a formula weight of 628.50 g/mol. The CAS number for this compound is 869113-09-7.
Top Ten Keywords/Synonyms
Health Benefits Umeclidinium bromide is primarily used for the treatment of chronic obstructive pulmonary disease (COPD), which is a respiratory disease that affects millions of people worldwide. It works by blocking the activity of muscarinic receptors in the lungs, which are responsible for controlling the contraction of smooth muscle and mucus production. By blocking these receptors, Umeclidinium bromide can help relax the airways, improve breathing, and reduce symptoms in patients with COPD.
Potential Effects In clinical trials, Umeclidinium bromide has been shown to be highly effective at improving lung function and reducing symptoms in patients with COPD. It has also been found to be well-tolerated, with few serious side effects reported. Additionally, Umeclidinium bromide has demonstrated good pharmacokinetic properties, meaning it is well-absorbed and distributed throughout the body, and is metabolized and eliminated from the body in a predictable manner.
Product Mechanism Umeclidinium bromide works by blocking the activity of muscarinic receptors in the lungs, which are responsible for controlling the contraction of smooth muscle and mucus production. Specifically, it binds to the M3 subtype of muscarinic receptors and prevents them from activating downstream signaling pathways that promote airway constriction and mucus production. By blocking these pathways, Umeclidinium bromide can help relax the airways, improve breathing, and reduce symptoms in patients with COPD.
Safety Overall, Umeclidinium bromide has been found to be safe and well-tolerated in clinical trials. However, like all medications, it does carry some risks of side effects and adverse events. Patients taking Umeclidinium bromide should be monitored regularly for any signs of allergic reactions, cardiovascular events, or other serious side effects.
Side Effects Some of the most common side effects reported with Umeclidinium bromide include dry mouth, constipation, and urinary tract infections. These side effects are usually mild to moderate in severity and go away on their own over time. More serious side effects, such as allergic reactions, cardiovascular events, or acute narrow-angle glaucoma, are rare but can occur in some patients.
Dosing Information Umeclidinium bromide is typically taken via inhalation, using a handheld device called a Respimat inhaler. The recommended dose for patients with COPD is 62.5 mcg once daily. Patients should follow their healthcare provider's instructions carefully when taking this medication.
Conclusion Umeclidinium bromide is a highly effective and well-tolerated medication used for the treatment of chronic obstructive pulmonary disease (COPD). As a long-acting bronchodilator and muscarinic antagonist, it helps relax the airways, improve breathing, and reduce symptoms in patients with this respiratory disease. While it does carry some risks of side effects and adverse events, overall it has been found to be safe and effective in clinical trials. Patients taking Umeclidinium bromide should work closely with their healthcare providers to ensure proper dosing and monitoring
